Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIVIG in Prevention of Maternal-Fetal HIV Transmission
NCT00000590Phase 3Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Sep 1991
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of anti-HIV immune serum globulin in human immunodeficiency virus infection (HIV) (2 arms), sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Infant HIV Status by p24 antigen assays, plasma viremia, or HIV co-culture assays at 24 months. Started Sep 1991; status: completed.
02
Drugs
anti-HIV immune serum globulin
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00000590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000590.